Interleukin 2 News and Research

RSS

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.

21 Jun 2022

New test can tell if you are immune to SARS-CoV-2

In a recent study published in the journal Nature Biotechnology, an international team of researchers developed and evaluated quantitative polymerase chain reaction (qPCR)-based assays to quantify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific functional T cell immunity.

15 Jun 2022

Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiation

Before a patient can undergo T cell therapy designed to target cancerous tumors, the patient's entire immune system must be destroyed with chemotherapy or radiation. The toxic side effects are well known, including nausea, extreme fatigue and hair loss.

8 Jun 2022

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.

6 Jun 2022

SARS-CoV-2 Omicron found to be more immune evasive than other variants among mild COVID-19 convalescent patients

Researchers evaluated the humoral and T lymphocyte immune responses against SARS-CoV-2 variants of concern among mild COVID-19 convalescent patients in South Australia.

19 May 2022

Study explores polyfunctionality of BNT162b2 COVID-19 vaccine-induced memory T-cells

Researchers assessed the impact of the BNT162b2 SARS-CoV-2 vaccine-induced memory T cells on the SARS-CoV-2 Omicron variant.

19 May 2022

Superior T-cell immunity in COVID vaccinated

A recent study published in the journal Public Library of Science (PLOS) ONE presented the T cell and humoral immune responses following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection against the SARS-CoV-2 original and mutant strains.

27 Apr 2022

Shared gene expression signatures in type 1 diabetics treated with IL-2 and COVID-19 patients

Researchers assess the impact of interval administration of LD-IL-2 was examined in 18 T1D patients who received a three-day dosing interval.

10 Apr 2022

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

A recent study investigated the potency and functionality of T-cell and humoral responses against the SARS-CoV-2 wild-type strain and its variants.

28 Mar 2022

Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

A recent study assessed the reactogenicity and immunogenicity induced by SARS-CoV-2 vaccines in adolescent individuals.

14 Mar 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Researchers develop an Omicron variant mRNA vaccine that is be more potent in generating nAbs as compared to other available vaccines.

6 Mar 2022

Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

In a new study, researchers evaluated the immune responses induced by the mRNA-based SARS-CoV-2 vaccination against SARS-CoV-2 variants in multiple myeloma patients.

1 Mar 2022

Immune responses in patients with varying degrees of SARS-CoV-2 infection

In a recent research article published in the journal PLoS ONE, researchers looked at immunological responses in relation to established risk factors for serious illness. This prospective cohort study reports on long-lasting SARS-CoV-2 specific antibody and T-cellular immune responses six months after infection in rt-PCR confirmed cases of different illness severity (community and hospitalized patients).

24 Feb 2022

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

A team of scientists from the United States has recently demonstrated that current coronavirus disease 2019 (COVID-19) vaccines induce robust spike-specific T cell responses against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Feb 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

In a new study, researchers evaluated SARS-CoV-2 vaccination-induced T cell responses cross-recognition among the early and novel SARS-CoV-2 variants.

26 Jan 2022

A common cold may boost the immune system against COVID-19

A recent groundbreaking research paper published in the journal Nature Communications reveals the association of circulating SARS-CoV-2-specific T cells at exposure with lack of infection – implying the protective role for cross-reactive immune T cells in coronavirus disease 2019 (COVID-19) and opening the door for second-generation vaccines that could circumvent spike-antibody immune escape variants.

11 Jan 2022

Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant

The current study examines the role of heterologous vaccination, an area that lacks much clarity.